AIDS Treatment Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2026-2035)

The global AIDS treatment market was valued at USD 31.50 Billion in 2025. It is poised to grow at a CAGR of 5.20% during the forecast period of 2026-2035, and reach USD 52.30 Billion by 2035. The market growth is driven by rising HIV prevalence, increasing awareness, government initiatives, improved diagnostics, advanced antiretroviral therapies, and expanding healthcare infrastructure.

Q1 2026 Market Updates

The US-Israel-Iran conflict, which escalated on 28 February 2026, is introducing serious risks to the global AIDS treatment market. The near-closure of the Strait of Hormuz has disrupted roughly 20% of global seaborne trade, while Gulf air-cargo capacity dropped 79% in the immediate aftermath of the conflict, driving a 22% reduction in worldwide air freight capacity. These disruptions are threatening the pharmaceutical supply chains that deliver antiretroviral (ARV) therapies to millions of patients globally.

Gulf countries serve as a critical pharmaceutical transit hub, where drugs and active pharmaceutical ingredients (APIs) from India, Europe, and China routinely pass before reaching Africa, Asia, and the Americas. Commercial shipping activity through the Strait of Hormuz remains approximately 90% below pre-war levels. For the AIDS treatment market, this disruption is particularly concerning because ARV supply chains are designed for continuous delivery, and many formulations include temperature-sensitive biologics that require cold-chain logistics. Cold-chain products, including certain ARV therapies, have narrow quality windows, making their supply chains inherently fragile.

India, which manufactures the majority of the world's generic ARV drugs, relies on Middle Eastern shipping corridors and air hubs such as Dubai and Doha for distributing these medications to sub-Saharan Africa, the region with the highest HIV burden. The rerouting of shipping around the Cape of Good Hope adds 10 to 14 days to delivery timelines and roughly USD 1 million in additional fuel costs per vessel. War-risk insurance premiums have surged twelvefold, and Hapag-Lloyd has imposed surcharges of up to USD 3,500 per container, all of which are inflating the delivered cost of generic ARV medications.

While short-term drug shortages remain limited due to existing inventory buffers in most national health systems, experts warn that these cushions are temporary. If the Strait of Hormuz disruption persists through Q2 2026, shortages of specific ARV formulations could emerge in countries with thin procurement pipelines. Rising energy costs, with Brent crude exceeding USD 126 per barrel, are also increasing manufacturing costs for API producers and generic drug makers, potentially leading to price increases for treatments that global health programmes have worked to make affordable.

Key Takeaways

Government: Governments in sub-Saharan African nations are reviewing national ARV stockpile levels and activating emergency procurement protocols with the Global Fund and PEPFAR to pre-position buffer stocks before shipping disruptions deepen. The WHO is coordinating with member states to identify alternative air freight routes bypassing Gulf hubs for time-sensitive ARV deliveries to high-burden countries. US and European regulatory agencies are expediting approvals for alternative generic ARV manufacturers whose supply chains are less dependent on Middle Eastern transit corridors.

Market: Generic ARV manufacturers in India face 10-15% increases in distribution costs as shipping reroutes and war-risk surcharges inflate the delivered price of medications to African and Asian markets. Global Fund procurement prices for first-line ARV regimens may need upward revision if logistics disruptions persist beyond Q2 2026, potentially reducing the number of patients that fixed budgets can cover. Pharmaceutical transit hubs in the Gulf, which process a significant share of India-to-Africa drug shipments, remain operating at approximately 10% of pre-war capacity.

Procurement: Procurement teams at national health agencies and international organizations are qualifying alternative shipping routes through East African ports and direct India-to-Africa ocean corridors to bypass disrupted Gulf transit points. Cold-chain logistics providers are reporting capacity constraints and premium pricing as demand for temperature-controlled air freight surges amid the 22% reduction in global air cargo availability. Emergency tenders for six-month ARV buffer stocks are being issued by several African health ministries to ensure treatment continuity for patients on lifelong antiretroviral therapy.

Key Market Trends and Insights

• By types, HIV-1 is anticipated to lead during the forecast period due to its significantly higher global prevalence.
• By drug types, integrase inhibitors held around 25% of the market share in the historical period.
• By route of administration, oral administration is likely to lead during the forecast period as it remains the most convenient option for patients.

Market Size and Forecast

• Market Size (2025): USD 31.50 Billion
• Projected Market Size (2035): USD 52.30 Billion
• CAGR (2026-2035): 5.20%